Description
Measure the ability of biologics to block immune checkpoint signals
PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of PD-1 by either of its ligands, PD-L1 or PD-L2, on an adjacent cell inhibits TCR signaling and TCR-mediated proliferation, transcriptional activation and cytokine production. Therapeutic antibodies and Fc fusion proteins designed to block the PD-1/PD-L1 interaction show promising results in clinical trials for the treatment of a variety of cancers.
The PD-1/PD-L1 Blockade Bioassay is a biologically relevant MOA-based assay that can be used to measure the potency and stability of antibodies and other biologics designed to block the PD-1/PD-L1 interaction.
Control Ab, Anti-PD-1, is a mouse anti-human PD-1 antibody that shows blocking activity for PD-1 with its ligands PD-L1 and PD-L2. It is intended for use as a control with the PD-1/PD-L1 Blockade Bioassay.
aAPC/CHO-K1 Cells are CHO-K1 cells with an engineered cell surface protein designed to activate cognate TCRs in an antigen-independent manner. The PD-L1 Negative aAPC/CHO-K1 Cells can serve as a negative control in the PD-1/PD-L1 Blockade Bioassay.
